Donald Notman Sells 6,301 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Donald Notman sold 6,301 shares of the stock in a transaction on Friday, January 31st. The shares were sold at an average price of $7.84, for a total value of $49,399.84. Following the completion of the sale, the insider now owns 204,563 shares of the company’s stock, valued at approximately $1,603,773.92. This represents a 2.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Donald Notman also recently made the following trade(s):

• On Tuesday, February 4th, Donald Notman sold 11,119 shares of Ocular Therapeutix stock. The shares were sold at an average price of $7.81, for a total value of $86,839.39.

Ocular Therapeutix Stock Up 4.0 %

Shares of NASDAQ:OCUL opened at $8.13 on Thursday. The firm has a market cap of $1.28 billion, a PE ratio of -6.16 and a beta of 1.22. The company has a fifty day simple moving average of $8.57 and a 200 day simple moving average of $9.01. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. Ocular Therapeutix, Inc. has a 12-month low of $4.06 and a 12-month high of $11.77.

Institutional Investors Weigh In On Ocular Therapeutix

Several hedge funds and other institutional investors have recently modified their holdings of OCUL. Assenagon Asset Management S.A. acquired a new position in Ocular Therapeutix in the third quarter worth about $24,584,000. Deltec Asset Management LLC lifted its holdings in Ocular Therapeutix by 0.6% during the 4th quarter. Deltec Asset Management LLC now owns 2,616,373 shares of the biopharmaceutical company’s stock worth $22,344,000 after buying an additional 16,300 shares during the last quarter. Braidwell LP grew its position in shares of Ocular Therapeutix by 36.3% in the 3rd quarter. Braidwell LP now owns 2,239,770 shares of the biopharmaceutical company’s stock worth $19,486,000 after acquiring an additional 596,000 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Ocular Therapeutix by 146.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,110,460 shares of the biopharmaceutical company’s stock valued at $9,661,000 after acquiring an additional 660,080 shares during the last quarter. Finally, Rosalind Advisors Inc. raised its position in shares of Ocular Therapeutix by 18.0% during the 3rd quarter. Rosalind Advisors Inc. now owns 885,000 shares of the biopharmaceutical company’s stock valued at $7,700,000 after acquiring an additional 135,000 shares in the last quarter. Institutional investors own 59.21% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on OCUL shares. Scotiabank assumed coverage on shares of Ocular Therapeutix in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $22.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Ocular Therapeutix in a report on Tuesday, December 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $16.71.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.